Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must provide signed inform consent prior to participation.~* BMI between 19,5 y 29 kg/m2.~* Normal ocular test in both eyes: IOP \</=21 mmHg. BCVAof \>/=0,8 (20/25)Snellen scale, or \</=0.1 LogMar.~* Normal fluorescein Clearance Test in both eyes.~* Normal funduscopy in both eyes.~Exclusion Criteria:~* Pregnant or breastfeeding females or those with a positive pregnancy test or who will not use a medically acceptable contraceptive method from selection and during the study.~* Current relevant disease.~* Previous chronic processes or with rebound characteristics that could interfere with study according investigator's judgment.~* Volunteers who have received pharmacological treatment, including medicinal plants, during the four weeks previous to beginning the study.~* Having used corticoids sporadically in the last 30 days whichever the route aof administration, or any med by ocular or nasal administration route.~* Case history of hypersensitivity to meds or any other allergic process.~* Visual alterations: previous eye surgery, glaucoma, use of lenses, uveitis or ocular surface pathology (dry eye, blepharitis).~* Volunteers with visual alteration with more than 3 dioptres in either eye.~* Volunteers who has participated in a clinical trial during the past fout months before study entry.~* Blood or derivate transfusion during the six previous months to study entry.~* Case history of drug or alcohol abuse or dependence.~* Positive result in test drug abuse during selection period.~* positive serology results to hepatitis B virus(HbsAg), virus C o VIH.~* Analytic alterations medically relevant, at investigator's judgement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- SYL1001 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).